-
The RRDi is looking for volunteer professional or amateur grant writers who would be willing to apply for corporate grants in behalf of the institute. Our volunteers have received three educational grants from Galderma, and if you are willing to learn how to become a grant writer, jump through all the hoops Galderma requires you to jump through, you could receive a portion of the grant money as a service to the RRDi since this is allowed in our charter. If you are a professional grant writer who has rosacea please consider spending some volunteer time organizing the RRDi's amateur grant writers committee. We prefer grant writers who have rosacea but if you don't have rosacea we still warmly invite you to write grants for our non profit organization. Anyone who wants to join the RRDi as a corporate member may volunteer to learn how to write grants as a volunteer amateur for the RRDi and become in time a professional grant writer. Please join. After logging into your account, contact us that you want to write grants for the RRDi. We will steer you into the correct direction, but basically you will be a volunteer writing grants for the RRDi and if you receive a grant you will be compensated. You may also receive a letter of recommendation if you volunteer for our non profit writing grants, get compensated, and help our non profit receive grants for rosacea research.
Grant Writers NeededThe RRDi will pay compensation to the grant writer upon successful allocation of money donated to the RRDi. Applying for Education Grants to Galderma has been our focus. You can also apply for grants to other sources.
Grant writers are enouraged to join the RRDi and use the private members forum in the GRANT WRITERS forum to discuss a team approach and discuss their concerns in the ASK THE MAC forum with our volunteer Medical Advisory Committee members.
If you are interested please join the RRDi and enter the members forum and look for the public and private grant writers sections. When you join online, please mention in the volunteer skills box that you are a grant writer or would like to write grants for the RRDi.
If you have any further questions please use our contact form.
Steps to Begin the Process to Be a Grant Writer for the RRDi
Be sure to fill in your contact details in your member profile including your mobile number, mailing address and at least two email addresses. You will be REQUIRED to confirm your primary email address to complete your registration, so please look for the confirmation email and follow the directions.
(2) Be sure to login AFTER you have done step 1 above and be sure that your profile shows all your contact information.
(3) Contact us using our contact form indicating you have joined the RRDi as a grant writer volunteer.
(4) Read ALL the posts in the Grant Writer Public Forum.
Some Helpful Links If You Are Considering Volunteering as a Grant Writer
How Much Are Grant Writers Paid Per Grant?
How to Break into the Lucrative World of Grant Writing
Grants/Proposal Writer Salary in the United States
How many total hours does it take to write a scientific grant proposal?
10 Things You Wish You Knew About Grant Writing
Volunteer Grant Writers
The RRDi relies on volunteer grant writers. However, if you are successful, we do reward your efforts. If you suffer from rosacea, that is definitely a plus for our organization that you understand what rosacea sufferers are going through and are actually doing something, writing rosacea grants, totally involved in trying to find the cure for rosacea, educating newbie rosaceans, or investigating the cause of rosacea through scientific study.
-
Posts
-
"Conclusions Patients with rosacea seem to have increased risk for depressive and anxiety symptoms also in general population. Physicians treating patients with rosacea should pay more attention to the psychosocial health of patients." Association of rosacea with depressive and anxiety symptoms: a general population study -
Int J Dermatol. 2023 Nov 28. doi: 10.1111/ijd.16920. Online ahead of print. ABSTRACT BACKGROUND: Rosacea is a chronic inflammatory dermatosis characterized by remissions and flares. Although the rosacea active treatment phase is well established, the long-term maintenance phase is still challenging. OBJECTIVE: To discuss and make recommendations on how to treat patients during the long-term maintenance phase for the main rosacea phenotypes. METHODS: A panel of six board-certified Brazilian dermatologists and one American dermatologist gathered to compose a consensus based upon an initial statement on how to treat rosacea during the long-term maintenance phase based on the methodology Nominal Group Technique. The experts discussed each factor based upon an initial statement on how to treat rosacea patients in the long-term maintenance phase. A sequence of comprehensive narrative reviews was performed; a questionnaire preparation about the definition of the maintenance phase and its management was presented; an interpersonal discussion and ranking of the ideas were conducted. Recommendations were made if the specialists had 75% agreement. RESULTS: The maintenance treatment phase, which starts by achieving IGA 0 or 1 grades at the active phase, should be considered at least during the 9-month period after remission. The recommendations of all treatments target this period. Daily skincare regimen and sunscreen are crucial. Active treatment phase should be recommended if signs or symptoms reappear or worsen. CONCLUSION: Maintenance phase success depends on patient's adherence to daily skin care, appropriate treatments, continued follow-up with dermatologist, and self-assessment to identify new signs and symptoms indicating disease relapse. PMID:38013632 | DOI:10.1111/ijd.16920 {url} = URL to article -
Res Sq. 2023 Nov 17:rs.3.rs-3611240. doi: 10.21203/rs.3.rs-3611240/v1. Preprint. ABSTRACT More than 20% of the population across the world is affected by non-communicable inflammatory skin diseases including psoriasis, atopic dermatitis, hidradenitis suppurativa, rosacea, etc. Many of these chronic diseases are painful and debilitating with limited effective therapeutic interventions. However, recent advances in psoriasis treatment have improved the effectiveness and provide better management of the disease. This study aims to identify common regulatory pathways and master regulators that regulate molecular pathogenesis. We designed an integrative systems biology framework to identify the significant regulators across several inflammatory skin diseases. With conventional transcriptome analysis, we identified 55 shared genes, which are enriched in several immune-associated pathways in eight inflammatory skin diseases. Next, we exploited the gene co-expression-, and protein-protein interaction-based networks to identify shared genes and protein components in different diseases with relevant functional implications. Additionally, the network analytics unravels 55 high-value proteins as significant regulators in molecular pathogenesis. We believe that these significant regulators should be explored with critical experimental approaches to identify the putative drug targets for more effective treatments. As an example, we identified IKZF1 as a shared significant master regulator in three inflammatory skin diseases, which can serve as a putative drug target with known disease-derived molecules for developing efficacious combinatorial treatments for hidradenitis suppurativa, atopic dermatitis, and rosacea. The proposed framework is very modular, which can indicate a significant path of molecular mechanism-based drug development from complex transcriptomics data and other multi-omics data. PMID:38014119 | PMC:PMC10680929 | DOI:10.21203/rs.3.rs-3611240/v1 {url} = URL to article
-
Skin Res Technol. 2023 Nov;29(11):e13525. doi: 10.1111/srt.13525. NO ABSTRACT PMID:38009046 | DOI:10.1111/srt.13525 {url} = URL to article
-
J Dermatol. 2023 Nov 27. doi: 10.1111/1346-8138.17051. Online ahead of print. ABSTRACT Granulomatous rosacea (GR) is a rare and distinct variant of rosacea. We report three cases of recalcitrant GR successfully treated with pulsed-dye laser (PDL) and provide experimental evidence supporting its potential as a treatment option. PDL treatment demonstrated remarkable efficacy in the three clinical cases, despite their resistance to conventional therapies. Chemokine ligand 9 (CXCL9), a key chemokine involved in inflammation and granuloma formation, was found to be increased in skin sections from all three patients. In vitro experiments using human monocytes and dermal fibroblasts demonstrated that PDL treatment significantly reduced CXCL9 expression in fibroblasts. These findings suggest that PDL may modulate CXCL9 secretion in fibroblasts, potentially limiting the recruitment of immune cells to the lesion. Although further research is needed to fully understand the precise mechanisms underlying the role of CXCL9 in GR, PDL may be a promising therapeutic approach for refractory GR. PMID:38009832 | DOI:10.1111/1346-8138.17051 {url} = URL to article
-
Clin Exp Dermatol. 2023 Nov 27:llad417. doi: 10.1093/ced/llad417. Online ahead of print. NO ABSTRACT PMID:38011317 | DOI:10.1093/ced/llad417 {url} = URL to article
-
